Irinotecan: Summary and future directions

ONCOLOGY

Volumn 15, Issue 1 SUPPL. 1, 2001, Pages 46-47

  Johnson, David H ^a,b,c  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; IRINOTECAN;

FORECASTING; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MORTALITY; MULTIMODALITY CANCER THERAPY; REVIEW; SMALL CELL CARCINOMA; SURVIVAL; UNITED STATES;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; FORECASTING; HUMANS; LUNG NEOPLASMS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 0035236186     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Negoro S, Fukuoka M, Niitani H, et al: Phase II study of CPT-11, new camptothecin derivative, in small cell lung cancer. Proc Am Soc Clin Oncol 10:241, 1991.
2. Masuda N, Fukuoka M, Kununoki Y, et al: CPT-11: A new derivative of camptothecin for the treatment of refractory or relapsed small cell lung cancer. J Clin Oncol 10:1225-1229, 1992.
3. Noda K, Nishiwaki Y, Kawahara M, et al: Randomized phase III study of irinotecan and cisplatin versus etoposide and cisplatin in extensive-disease small cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511). Proc Am Soc Clin Oncol 19:483a, 2000.
4. Negoro S, Fukuoka M, Masuda N, et al: Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. J Natl Cancer Inst 83:1164-1168, 1991.
5. Masuda N, Fukuoka M, Takada M, et al: CPT-11 in combination with cisplatin for advanced non-small-cell lung cancer. J Clin Oncol 10:1775-1780, 1992.
6. Masuda N, Fukuoka M, Kudoh S, et al: Phase I and pharmacologic study of irinotecan in combination with cisplatin for advanced lung cancer. Br J Cancer 68:777-782, 1993.
7. Fukuoka M, Masuda N: Clinical studies of irinotecan alone and in combination with cisplatin. Cancer Chemother Pharmacol 34(suppl):S105-S111, 1994.
8. DeVore RF, Johnson DH, Crawford J, et al: Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 17:2710-2720, 1999.
9. Wozniak AJ, Crowley JJ, Balcerzak SP, et al: Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 16:2459-2465, 1998.
10. Schiller JH, Harrington D, Sandler A, et al: A randomized trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 19:1a, 2000.
11. Sause W, Kolesar P, Taylor S, et al: Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer. Chest 117:358-364, 2000.
12. Kris M, Ranson M, Ferry D, et al: Phase I study of oral ZD1839 (Iressa), a novel inhibitor of epidermal growth factor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity, Clin Cancer Res 5(suppl):3749S, 1999.